Rectal Cancer Clinical Trial
A clinical trial for rectal cancer patients will test a technique that delivers high doses of radiation directly to rectal tumors.
The study will evaluate the effectiveness of endorectal brachytherapy (EBT) in patients with stage II and III low rectal cancers, with tumors less than 12 centimeters from the anus.
Who Can Join?
Eligible rectal cancer patients may include those with:
- Stage II and III rectal cancer
- Rectal cancer that has not spread to other parts of the body
What is involved in the clinical trial?
As part of the experimental treatment, patients will receive four days of EBT before surgery, in contrast to the standard treatment of 28 days (over five to six weeks) of external (X-ray) beam- radiation therapy and chemotherapy delivered before surgical removal of the tumor.
EBT uses a wire containing a high-dose radiation source threaded through a cylinder-shaped applicator inserted into the patient's rectum. As the radiation moves slowly through the applicator, the wire delivers a high dose of focused radiation to the surface of the tumor. Normal tissue farther away from the applicator, including the bladder, small intestine and reproductive organs, receives a lower dose than with standard "long-course" radiation therapy. The treatment is delivered for 15 minutes a day over four days, and radiation sources are completely removed from the body at the end of each session. Patients have a six-to-eight-week recovery period following EBT before they undergo surgery.
This study is funded by NucletronTM.
For more information or to see if you qualify, call Beth Griffith at 410-502-9243 or email email@example.com.